3SOF

Worth a look...........Going to a buck.

Volume is big.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical's first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

For obese or overweight individuals, BDC-03's potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body's inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com.

Excellent day, chart looks good.

Wow, nice find. it has a nice breakout. Looks like this stock is under accumulation for 2 months and today broke out with more than 600% of daily vol.
The momo will be in it for a few weeks. I will watch for a entry, thanks Holygrale.

Yep a great breakout on high volume with no news. Something is going on here for sure.

Last time it ran with big momentum was November starting around the same price as yesterdays action. Over 2 months it went from $0.52 to $1.70, again on strong volume.

Worth watching.

Scottrade has it "on watch" ...whatever that means.  Basically, I couldn't place a buy online (CR1 alert/error?) I had to call them.  The gentleman told me it's due to "unusual trading patterns"....like huge volume with no news    or    We shall see.

I just picked up a 1000 @$0.65 for a gamble.  I'm sure it'll retrace before/if it goes higher, but ya just never know...G-pattern in the making maybe?

Applaude for the heads up.

Jody

This one has alot of potential.........Not sure whats going on, but hope the news is good. If you go to their website the company is pretty impressive.

I picked up "the other half" when it dipped below the 50dma for an avg of $.55 (only using $1000 due to risk).

It needs to go up from here (sitting on 50dma) or I'm more than likely out.

GLTA...Jody

Quote from: 422fwhp on October 11, 2006, 09:19:50 AM
I picked up "the other half" when it dipped below the 50dma for an avg of $.55 (only using $1000 due to risk).

It needs to go up from here (sitting on 50dma) or I'm more than likely out.

That'll work...

This could set up a G pattern. With the absence of Elite (I hope he is well), I have pulled together all his G pattern data (from the various threads) added or changed based on my own observations / criteria and put together a simple set of rules for playing this type of penny move. As there are many new members who would never have come across Elite and the G pattern I will post the simple rules in a new thread somewhere so anyone interested can investigate it.

WOOT!  Anyone else riding this one?  G-pattern?

Nice healthy correction...still looks bueno, imo. 

Comments welcome.

Quote from: 422fwhp on November 22, 2006, 06:12:05 AM
WOOT!  Anyone else riding this one?  G-pattern

On the recent PYTO pullback it was quite prolonged and went below the initial breakout low from October, so in absolute sense it does not qualify as a G pattern. However it is a nice volume backed correction off the floor which is set just below $0.4. Good luck if you are in this one.

thx...I'm in at $0.39 and $0.42 and sold 1/4 posoition @$0.56

Wonder if I can sell the rest ta $0.65 or higher.

Financials:  http://finance.yahoo.com/q/is?s=pyto.ob

Income Statement Get Income Statement for: 




View: Annual Data | Quarterly Data All numbers in thousands
PERIOD ENDING 30-Sep-06 30-Jun-06 31-Mar-06 31-Dec-05
Total Revenue -   -   -   -   
Cost of Revenue 5   (803) 810   (6)

Gross Profit (5) 803   (810) 6   

Operating Expenses
Research Development 191   157   137   135   
Selling General and Administrative 803   1,570   107   1,716   
Non Recurring -   -   -   -   
Others -   -   -   -   
 
Total Operating Expenses -   -   -   -   


Operating Income or Loss (998) (924) (1,054) (1,845)

Income from Continuing Operations
Total Other Income/Expenses Net 4   5   4   1   
Earnings Before Interest And Taxes (994) (919) (1,050) (1,844)
Interest Expense -   -   -   -   
Income Before Tax (994) (919) (1,050) (1,844)
Income Tax Expense -   -   -   -   
Minority Interest -   -   -   -   
 
Net Income From Continuing Ops (994) (919) (1,050) (1,844)

Non-recurring Events
Discontinued Operations -   -   -   -   
Extraordinary Items -   -   -   -   
Effect Of Accounting Changes -   -   -   -   
Other Items -   -   -   -   


Net Income (994) (919) (1,050) (1,844)
Preferred Stock And Other Adjustments -   -   -   -   

Net Income Applicable To Common Shares ($994) ($919) ($1,050) ($1,844)

up 18%